Introduction
Cells of the mononuclear phagocyte series perform a large array of functions that are crucial to the integrity of the immune system and for host defense (1) (2) (3) . In addition to strictly cellular functions such as antigen processing and presentation, antibody-dependent and antibody-independent cellular cytotoxicity and killing of both intracellular and extracellular miAddress reprint requests to Dr. Reiner Receivedfor publication 1 August 1988 and in revisedform 9 February 1990.
croorganisms, mononuclear phagocytes also produce and secrete a variety ofcytokines that have potent, pleiotropic effects within the host (2) . Important examples of the latter are interleukin 1 (IL-1) and tumor necrosis factor-a (TNF-a),' two cytokines which mediate a large and frequently overlapping repertoire of biological activities (4) (5) (6) (7) (8) . In particular, IL-l and TNF-a have been shown to be important elements in the host response to microbial invasion. For example, both IL-1 and TNF-a are produced in response to a variety of microbes and microbial products (4, 6) and in turn these cytokines have been shown to mediate antimicrobial activities both in vitro and in vivo (9) (10) (11) (12) . Paradoxically, in spite of the prominent role of mononuclear phagocytes in host defense, a large number of diverse microorganisms have evolved the capacity to establish a state of intracellular parasitism within these cells. This suggests the possibility that in order to insure their own survival, these organisms may use strategies designed to either evade or subvert the regulatory or effector functions of their target cells. Protozoa of the genus Leishmania are an example of a group of organisms that have adapted remarkably well in respect to their ability to infect, propagate and persist within mononuclear phagocytes (13, 14) . Given the pivotal roles of mononuclear phagocytes and oftheir cytokine products in mammalian homeostasis, it is important to understand how these functions may be perturbed during chronic intracellular infection.
Moreover, with respect to Leishmania in particular, understanding how cytokine production is modulated in infected mononuclear phagocytes may be of fundamental importance to the immunobiology of the leishmaniases. Support for this concept derives from recent findings that demonstrated a protective role for TNF-a in experimental leishmaniasis (15) and from studies in which interferon-y (IFN-y), a lymphokine that potentiates monocyte cytokine production (16) (17) (18) (19) , was shown to have therapeutic efficacy in human visceral leishmaniasis (20) . Based upon these considerations, in the present study the modulation of IL-1 and TNF-a production by human monocytes during infection with Leishmania donovani (the causative agent of visceral leishmaniasis in the Old World) was examined. The question of whether IFN-'y could modulate human monocyte responses to L. donovani for the production of TNF-a and IL-I was also studied.
Methods
Leishmania and leismania lysate. Amastigotes of the Sudan strain 2S of L. donovani used in this study were isolated from spleens of male U/mg), recombinant human TNF-a (sp act 5 X 107 U/mg), and the cDNA probes for human IL-1,f (22) and human TNF-a (23) were generous gifts from Genentech Inc., South San Francisco, CA.
Cell preparation and culture. Peripheral blood mononuclear cells were isolated from buffy coats (obtained from normal human volunteers by the British Columbia and Yukon Division of the Canadian Red Cross) by centrifugation (800 g for 15 min) over Histopaque. After three washes in HBSS, the cells were resuspended in RPMI 1640 with 10% human serum at I X 107 viable cells per ml and dispensed into 150-cm2 tissue culture flasks (20 ml per flask for the preparation of cellular RNA) and incubated at 37°C in a 5% C02/95% air, humidified atmosphere for 45 min. Nonadherent cells were removed by vigorous washing with divalent cation-free HBSS (37°C) and the flasks were replenished with RPMI 1640 supplemented with 20% fresh human serum for culture with or without the addition of various stimuli. Adherent monolayers prepared in this manner were 89±5% monocytes by morphologic and phagocytic criteria as determined by microscopic examination of Diff-Quik (B4132-1, CanLab, Vancouver, BC) stained preparations.
Monocyte supernatants for IL-I and for TNF-a assays were generated by culturing 1 X 106 peripheral blood mononuclear cells per chamber of eight-chamber Lab-Tek chamber slides (no. 4808, Miles Scientific, Inc., Naperville, IL) in DME/10% heat-inactivated fetal bovine serum (FBS) (lot 1111646, Hyclone Laboratories, Logan, Utah) for 60 min at 37°C in 5% C02/95% air. Nonadherent cells were removed by washing as above for flasks, and the chambers were replenished with DME 10% FBS with or without stimulants. After overnight incubation (12-16 h), cell-free supernatants were collected and either assayed immediately or stored at -70°C. Monolayers prepared in this manner were 86±5% monocytes by both morphologic and phagocytic criteria as described above for flask cultures.
IL-I assay. IL-l activity in monocyte supernatants was assayed by Reduced IL-I content of supernatants derived from cells preinfected with Leishmania and secondarily stimulated with either S. aureus or with LPS was not related to altered kinetics of IL-I release. Thus, as shown in Fig. 3 , irrespective of the duration of incubation of Leishmania-infected cells with LPS, in comparison to LPS treated control cells, supernatants of infected monocytes had decreased IL-1 activity. In addition, reduced IL-1 content of supernatants derived from infected cells was shown (Table II) not to be related to intracellular accumulation of cytokine.
Additional experiments were carried out to determine whether inhibition ofIL-I production by Leishmania required infection with intact organisms. To examine this question, 4 h before stimulation with S. aureus, cells were either infected with Leishmania or treated with a soluble parasite lysate (prepared as described in Methods). As shown in Table III , cells preinfected with Leishmania had significantly decreased responses to S. aureus for IL-I production. In contrast, in two of three experiments, pretreatment of cells with the parasite lysate (10 ,ug/ml) did not significantly affect the IL-l response to Figure 6 , supernatants of cells infected with L. donovani for -16 h had no detectable increase in immunoreactive TNF-a content when compared with control cells. In contrast, stimulation of monocytes with either S. aureus or with LPS was associated with significant increases in TNF-a content. Monocyte supernatants were also assayed for TNF-a bioactivity in the L929 cytotoxicity assay. The results (data not shown) indicated that TNF-a bioactivity in monocyte supernatants paralleled exactly the levels of immunoreactive cytokine shown in Fig. 6 .
In contrast to the findings with IL-1, monocytes preinfected with Leishmania responded normally to secondary stimuli for the production of TNF-a. As shown in Fig. 6 with either S. aureus or LPS alone. These results were also confirmed by measurements of TNF-a bioactivity in monocyte supernatants (data not shown). Consistent with these observations, was the finding that the steady-state level of TNF-a mRNA in Leishmania-infected, S. aureus-treated cells was equivalent to the level of TNF-a mRNA detected in S. aureus-induced normal monocytes (Fig. 5 B) .
Modulation by IFN--y ofL. donovani effects on monocyte IL-1 production. preinfrcted with Leishmania for 4 h were markedly unresponsive to S. aureus for the production ofIL-1. Treatment ofcells with IFN-y for 4 h before infection, however, abrogated Leishmania-induced inhibition of the IL-I response to S.
aureus (n = 6). The protective effect of IFN-'y was found to be time dependent. Thus, as shown in Fig. 7 , significant enhancement of the response to S. aureus (by Leishmania-infected cells) was also seen when IFN-y and Leishmania were added simultaneously. On the other hand, when added at progressively later time points (relative to infection) the protective effect of IFN-'y was eventually lost.
To examine whether there were conditions under which monocytes would respond to Leishmania alone by producing IL-1, cells were primed with IFN-,y before infection. The results shown in Fig. 8 The ability of cytokine treatment to prime cells to respond to Leishmania by producing IL-I was also time-dependent. As shown in Fig. 8 , the simultaneous addition ofLeishmania and IFN-'y resulted in significantly less priming for IL-I production when compared to cytokine pretreatment. When leishmania infection was followed either 2 or 4 h later by the addition of IFN-'y, the ability to convert cells from being IL-I nonresponders to IL-1 responders was progressively lost. The priming effect of IFN-'y for monocyte IL-I synthesis in response to Leishmania was found to vary amongst monocyte donors. Thus, significant priming was observed in six out of nine experiments using cells from distinct donors. This variability may be related to heterogeneous responses to IFN-y.
IFN-,y primes monocytes to produce TNF-a in response to L. donovani. As shown in Table IV , monocytes primed with IFN-7 produced large amounts of immunoreactive TNF-a in response to infection with Leishmania (priming was observed in three out of five separate experiments using cells from individual donors). Treatment of cells with either IFN-'y or Leishmania alone resulted in minimal or negligible amounts of TNF-a production (when compared to unstimulated cells). On the other hand, the content of immunoreactive TNF-a detected in supernatants of cells (from three of five donors) primed with IFN-y for 4 h before the addition of Leishmania was increased significantly (from 7-to 30-fold) in comparison to supernatants of cells treated with Leishmania alone.
Discussion
The results of the present study demonstrate that amastigotes of L. donovani are capable of infecting human monocytes without stimulating these cells to synthesize IL-I or to secrete IL-I activity into their supernatants. This finding is in agreement both with previous experiments from this laboratory which examined the interaction of this organism with murine macrophages (25) and with the data of Crawford et al. (29) . The latter workers reported that human monocytes infected with Leishmania major also did not produce IL-i. On the other hand, these findings are in direct contrast to those recently reported by Cillari and co-workers demonstrating that murine macrophages responded to infection with L. major by producing IL-1 (30) . The explanation for the divergent findings ofthese two studies that examined L. major is not known. The potential difference, however, between L. donovani and L. IFN-'y + L. donovani* 2,070 6,400 2,500 147 526
Monolayers of human monocytes, prepared as described in the legend to Fig. 1 , were either untreated or infected with L. donovani at a parasite/cell ratio of 10:1. Supernatants were removed after 16 h of culture and analyzed for immunoreactive TNF-a by ELISA. For the five experiments shown the infection rate was 88.9±7.8% (mean±SD) with a mean of 8.1±2.9 amastigotes per cell. * IFN-y was used at 200 U/ml. tMonolayers treated with both IFN-,y and L. donovani were incubated with lymphokine for 4 h before infection. The values for immunoreactive TNF-a in supernatants of cells treated with L. donovani alone and those detected in supernatants of cells treated with IFN-y + L. donovani were log transformed and compared by Student's paired t test (two-tailed). The mean increase in TNF-a content associated with IFN-y pretreatment was significant at P = 0.04.
major with respect to the production of IL-I by infected mononuclear cells may be related to fundamental differences in the immunobiology of infection with these two species of Leishmania. The data presented above furthermore establish that cellular unresponsiveness to Leishmania donovani with respect to IL-I synthesis is related to the absence of IL-1,B mRNA accummulation following monocyte infection (Fig. 2) . This finding is consistent with and provides an explanation for our prior inability to detect either intracellular, membrane or secreted IL-I activities associated with leishmania-infected murine macrophages (25) .
The data presented herein also indicate that in addition to infecting human monocytes without inducing IL-1 production, L. donovani is capable of inhibiting monocyte IL-1 responses to other stimuli. Inhibition by Leishmania of the IL-I response to either S. aureus or LPS was likely related predominantly to mechanisms affecting translation of IL-1j mRNA or possibly to stability of translated protein. This conclusion is supported by several findings including (a) normal steady-state levels of either S. aureus (Fig. 5) or LPS-induced (Fig. 4) IL-1I3 mRNA in Leishmania-preinfected cells, (b) decreased supernatant content of IL-I was not explained by altered kinetics of IL-I release induced by infection (Fig. 3) , and (c) the absence of the intracellular accummulation of IL-I in infected cells (Table II) . Although the predominant mechanism of inhibition of S. aureus-induced IL-I synthesis in Leishmania-in- thesis at different levels along the induction pathway, according to the secondary stimulus involved (i.e., S. aureus vs. LPS) is consistent with previous studies in which stimulus-specific regulation of IL-I production by mononuclear phagocytes was shown. For instance, Kunkel et al. (31) found IL-I production by murine macrophages to be differentially regulated according to whether the inducing stimulus used was phagocytic or soluble. Furthermore, Fenton and co-workers (32) demonstrated that independent mechanisms regulated phorbol ester vs. LPS induction of IL-I production by THP-1 cells, by human monocytes and by the HL-60 myelocytic cell line.
Inhibition of monocyte IL-I production by Leishmania both at the level of mRNA accummulation (in response to S. aureus) as well as posttranscriptionally (in response to LPS or S. aureus), is also consistent with data demonstrating that IL-I expression is subject to regulatory control at each of these levels. Thus, glucocorticoids have been shown to suppress IL-1 gene transcription and mRNA accummulation in cells of the promonocyte cell line U937 (33, 34) . Lew and coworkers also reported suppression of LPS-induced IL-la and IL-1# mRNA accummulation in adherent human monocytes treated with prednisolone (35), although Kern et al. noted only post-transcriptional suppression of IL-1 production in dexamethasone treated human monocytes in suspension culture (36) . Furthermore, both glucocorticoids (33, 36) and elevated levels of prostaglandins (34) have been shown to downregulate IL-l expression posttranscriptionally through a cAMP-dependent pathway (34, 37) . In regard to the latter, we have previously shown that macrophages respond to infection with L. donovani with increased synthesis of prostaglandin E2 (38) and such a mechanism could explain a predominantly posttranscriptional suppression of the IL-I response to either LPS or S. aureus in Leishmania-infected cells. Attempts to demonstrate such a relationship by treating cells with cyclooxygenase inhibitors such as indomethacin or sodium meclofenamate prior to and during Leishmania infection, did not result in the restoration the IL-I response to LPS (data not shown). A negative result from such an experiment does not, however, provide definitive evidence to exclude a role for prostaglandins. Thus, as has been shown by us (38) and by others (39, 40) these putative cyclooxygenase inhibitors lack specificity in that they also inhibit the metabolism of arachidonic acid via the lipoxygenase pathway. This consideration is of particular importance since evidence has been presented to indicate that lipoxygenase products of arachidonic acid promote monocyte IL-1 synthesis (41, 42) . The failure of putatively specific cyclooxygenase inhibitors to restore the IL-I response to LPS in Leishmania-preinfected cells could thus be related to countervailing effects of inhibitors on these dual pathways of arachidonic acid oxygenation.
As was the case for IL-1, the results of the present study furthermore indicate that infection of human monocytes with L. donovani did not result in increased TNF-a activity in monocyte supernatants. This result may be interpretated to indicate that Leishmania did not induce cytokine synthesis, since > 90% of TNF-a produced by fresh monocytes is found extracellularly (16) . This interpretation is supported by the finding that TNF-a mRNA accummulation was not induced in monocytes in response to Leishmania alone (Fig. 5 ).
These findings demonstrate, therefore, that neither IL-I nor TNF-a are produced by human monocytes in response to Leishmania. Of particular interest, however, was the observa-tion that these two cytokines were not coordinately regulated during infection with Leishmania. Thus, in response to secondary stimuli the production of IL-I was found to be inhibited in leishmania infected cells, but the production of TNF-a was unaffected. This selective inhibitory effect of Leishmania on the production of these two cytokines is consistent with the findings of Burchett et al., indicating that the synthesis of IL-1 and TNF-a in human monocytes are not coordinately regulated (16) .
The finding that human monocytes were unresponsiveness to Leishmania with respect to cytokine production, and that infection inhibited IL-1 induction in response to secondary stimuli, prompted examination of whether these events could be modified by IFN--y. This approach was based upon data demonstrating the capacity of this lymphokine to upregulate IL-1 production by both freshly isolated human monocytes and by in vitro monocyte-derived macrophages (16) (17) (18) (19) . Treatment of cells with IFN--y before infection, primed cells to respond to L. donovani by producing both IL-l (n = 6 out of 9 experiments) and TNF-a (n = 3 out of 5 experiments). Compared to cells that were not treated with lymphokine, the priming effect of IFN-,y was greater (in absolute, but not relative terms) for monocyte production of TNF-a (in response to Leishmania) than it was for the synthesis ofIL-I (compare Fig.  8 and Table IV ). This result is in agreement with previous results (16) indicating a quantitatively greater priming effect of IFN--y on monocyte production of TNF-a in comparison to IL-l.
In addition to converting cells from a nonresponsive state to a responsive one, with respect to cytokine production upon exposure to Leishmania, IFN-'y was also able to abrogate parasite-induced inhibition ofthe IL-1 response to a second stimulus (Fig. 7) . Both in the case of priming for cytokine production (Fig. 8) and also in preventing inhibition of the IL-l response (Fig. 7) , the efficacy of lymphokine treatment was time dependent. Treatment with IFN-,y before exposure to Leishmania was required for maximal responses. When lymphokine treatment was initiated as little as 2 h after leishmania infection efficacy was lost.
Although the exact mechanism(s) whereby IFN--y modulated monocyte IL-1 and TNF-a responses to Leishmania are as yet unknown, this lymphokine has been shown to increase the duration of transcription of the genes encoding these cytokines when cells were activated by LPS (16) . Enhancement by IFN-y of cytokine mRNA stabilities were also described (16) . In addition, priming of cells by IFN--y for increased IL-l responses to various stimuli may be related to modulation of monocyte arachidonic acid metabolism by this lymphokine. Prostaglandins of the E series inhibit monocyte IL-I production (31, 37) and IFN-y has been shown to downregulate monocyte PGE2 synthesis in response to a variety of agonists (43) (44) (45) (46) . Modulation by IFN-y of monocyte PGE2 production in response to Leishmania, therefore, could potentially explain its capacity to upregulate cytokine production during in vitro infection.
Data from both the present and from previous experiments (25) clearly show that the direct interaction of L. donovani with mononuclear phagocytes does not result in the production of IL-1. In addition, here we present evidence that TNF-a is also not produced under these conditions. Considering that IL-1 and TNF-a represent two of the three (interferon-a being the third) currently recognized endogenous pyrogens (47) , these data must be viewed in light ofthe fact that fever is nearly a constant feature in patients with visceral leishmaniasis ( 13, 14) . At (20) . The mechanism accounting for the efficacy of IFN-'y in this setting may have been related to the direct induction of monocyte killing of Leishmania. On the other hand, the findings of the present study, that IFN--y primes monocytes to produce both TNF-a and IL-I in response to Leishmania, suggest a potential alternative mechanism by which IFN--y may mediate its therapeutic effect. Thus, both IL-I and TNF-a have been shown to mediate antimicrobial effects against intracellular pathogens (3, (9) (10) (11) (12) . Moreover, and of direct relevance to the results of the present study, are the recent findings of Titus and coworkers that demonstrated a protective role for TNF-a in experimental leishmaniasis (15) . This suggests the possibility that priming by IFN--y for monocyte TNF-a production (and perhaps IL-1) in response to Leishmania is a potential mechanism by which IFN-,y mediates its therapeutic effect in vivo. Although direct evidence that IL-I plays a role in the pathogenesis of leishmania infections has not yet been presented, it is reasonable to consider this a likely possibility given the considerable extent to which the biological activities ofIL-I and TNF overlap (4) (5) (6) (7) (8) . Furthermore, the ability of IFN-y to promote monocyte IL-I production in response to Leishmania may have other indirect effects on the immune response. Thus, numerous investigators have demonstrated cellular immune defects and deficiencies of lymphokine production in visceral leishmaniasis (21, 53-55 ). The precise relationship of these immune deficiencies to inhibition of IL-I production (which plays a central role in the evolution of a cellular immune response) by Leishmania remains to be defined. Nevertheless, the ability of mononuclear phagocytes primed in vivo with IFN-,y to respond to Leishmania by producing IL-1 could potentially reverse some of these immune defects. Such an effect would favor the evolution of a protective, antileishmanial cell-mediated immune response, which is critical to ultimate cure (13, 14) .
